알레르기 진단 및 치료 시장 규모, 점유율 및 동향 분석 보고서 : 유형별, 알레르겐 유형별, 검사 유형별, 지역별, 부문 예측(2025-2033년)

Allergy Diagnostics And Therapeutics Market Summary

The global allergy diagnostics and therapeutics market size was estimated at USD 34.42 billion in 2024 and is projected to reach USD 78.00 billion by 2033, growing at a CAGR of 9.7% from 2025 to 2033. Some of the major factors driving the market are rising incidence of allergies, advancements in technology and launch of new products, and high adoption of immunotherapy drugs.

In November 2022, the Global Allergy and Airways Patient Platform reported that approximately 30-40% of people today have one or more allergies, and the number of people with allergies has been increasing over the past 20 years. Furthermore, changing lifestyle and growing pollution are some of the key factors contributing to the increasing incidence of allergic conditions. The introduction of therapeutically advanced drugs namely immunotherapy, which solves unmet patient needs, is expected to boost market growth over the forecast period. For instance, in February 2024, the U.S. Food and Drug Administration approved Xolair (omalizumab) injection for immunoglobulin E-mediated food allergy in certain adults and children 1 year or older for the reduction of allergic reactions (Type I), including reducing the risk of anaphylaxis, that may occur with accidental exposure due to more than one food. Also, Xolair is intended for repeated use to reduce the risk of allergic reactions and is not approved for the immediate emergency treatment of allergic reactions, including anaphylaxis.

The rising prevalence of allergies is one of the important reasons driving the growth of the allergy therapeutics market over the predicted period. High risk factors for chronic respiratory disorders include increased exposure to outdoor and indoor air pollution, as well as occupational exposure. Allergies are far more common in cities than in rural areas, owing to increased exposure to environmental contaminants due to industrial activity and urbanization.

According to statistics published by WHO in January 2024, around 1 in 4 children and 1 in 3 adults have a seasonal allergy in the U.S. Nearly 6% of children and adults in the U.S. suffer from a food allergy, with the rate being highest among black, Asian, and Hispanic individuals. Similarly, as per data from the Asthma and Allergy Foundation of America, in 2021, in the U.S., about 81 million people were diagnosed with seasonal allergic rhinitis, representing around 26% affected adults and 19% affected children.

Increasing demand for IVD testing is likely to drive the allergy diagnostics and therapeutics market over the forecast period. In vitro blood tests are used to diagnose food, inhalation, skin, and medication allergies. These tests have several advantages, including the fact that they are minimally invasive, cost-effective, and user-friendly, which is expected to provide profitable growth prospects in this market. Furthermore, the development of low-cost and effective in vitro diagnostic tests for allergy detection, increased lab automation, and an increase in reagent rental agreements are all projected to contribute to market expansion in the future years.

Global Allergy Diagnostics and Therapeutic Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2030. For this report, Grand View Research has segmented the global allergy diagnostics & therapeutics market based on type, allergen type, test type, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Diagnostics
  • Instruments
  • Consumables
  • Services
• Therapeutics
  • Antihistamines
  • Decongestants
  • Corticosteroids
  • Mast Cell Stabilizers
  • Leukotriene Inhibitors
  • Nasal Anti-cholinergic
  • Immuno-modulators
  • Epinephrine
  • Immunotherapy
• Allergen Type Outlook (Revenue, USD Million, 2021 - 2033)
• Food
  • Dairy Products
  • Poultry Product
  • Tree Nuts
  • Peanuts
  • Shellfish
  • Wheat
  • Soy
  • Other Food Allergens
• Inhaled
• Drug
• Others allergen types
• Test Type Outlook (Revenue, USD Million, 2021 - 2033)
• In Vivo Tests
  • Skin Prick Test
  • Intradermal Test
  • Patch Test
• In Vitro Tests
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Allergy Diagnostics and Therapeutics Market: Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Product Method
    • 1.1.1.2. Allergen Type Segment
    • 1.1.1.3. Test Type Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Allergy Diagnostics and Therapeutics Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Product Snapshot
• 2.3. Allergen Type Snapshot
• 2.4. Type Snapshot
• 2.5. Competitive Landscape Snapshot

Chapter 3. Allergy Diagnostics and Therapeutics Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
  • 3.4.1. Rising incidence of allergies
  • 3.4.2. Advancements in technology and launch of new products
  • 3.4.3. High adoption of immunotherapy drugs
• 3.5. Market Restraint Analysis
  • 3.5.1. Low adoption and penetration in developing countries due to the high cost of technology
  • 3.5.2. Lack of allergen standardization
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis
• 3.8. Pipeline Analysis

Chapter 4. Allergy Diagnostics and Therapeutics Market: Type Estimates & Trend Analysis

• 4.1. Allergy Diagnostics and Therapeutics Market: Test Method Movement Analysis
• 4.2. Diagnostics
  • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.3. Instruments
  • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.4. Consumables
  • 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Services
  • 4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Therapeutics
  • 4.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Antihistamines
  • 4.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Decongestants
  • 4.8.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.9. Corticosteroids
  • 4.9.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.10. Mast Cell Stabilizers
  • 4.10.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.11. Leukotriene Inhibitors
  • 4.11.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.12. Nasal Anti-cholinergic
  • 4.12.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.13. Immuno-modulators
  • 4.13.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.14. Epinephrine
  • 4.14.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.15. Immunotherapy
  • 4.15.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Allergy Diagnostics and Therapeutics Market: Allergen Type Estimates & Trend Analysis

• 5.1. Allergy Diagnostics and Therapeutics Market: Mode Movement Analysis
• 5.2. Food
  • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.3. Dairy Products
  • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. Poultry Product
  • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Tree Nuts
  • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Peanuts
  • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Shellfish
  • 5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Wheat
  • 5.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.9. Soy
  • 5.9.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.10. Other Food Allergens
  • 5.10.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.11. Inhaled
  • 5.11.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.12. Drug
  • 5.12.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.13. Others allergen types
  • 5.13.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Allergy Diagnostics and Therapeutics Market: Test Type Estimates & Trend Analysis

• 6.1. Allergy Diagnostics and Therapeutics Market: Type Movement Analysis
• 6.2. In Vivo tests
  • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.3. Skin Prick Test
  • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. Intradermal Test
  • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Patch Test
  • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. In Vitro tests
  • 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Allergy Diagnostics and Therapeutics Market: Regional Business Analysis

• 7.1. Regional Market Snapshot
• 7.2. North America
  • 7.2.1. North America Allergy Diagnostics and Therapeutics Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. U.S. Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
    • 7.2.2.2. Key Country Dynamics
    • 7.2.2.3. Regulatory Framework
    • 7.2.2.4. Reimbursement Scenario
    • 7.2.2.5. Competitive Scenario
  • 7.2.3. Canada
    • 7.2.3.1. Canada Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
    • 7.2.3.2. Key Country Dynamics
    • 7.2.3.3. Regulatory Framework
    • 7.2.3.4. Reimbursement Scenario
    • 7.2.3.5. Competitive Scenario
  • 7.2.4. Mexico
    • 7.2.4.1. Mexico Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
    • 7.2.4.2. Key Country Dynamics
    • 7.2.4.3. Regulatory Framework
    • 7.2.4.4. Reimbursement Scenario
    • 7.2.4.5. Competitive Scenario
• 7.3. Europe
  • 7.3.1. Europe Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
  • 7.3.2. UK
    • 7.3.2.1. UK Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
    • 7.3.2.2. Key Country Dynamics
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. Reimbursement Scenario
    • 7.3.2.5. Competitive Scenario
  • 7.3.3. Germany
    • 7.3.3.1. Germany Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
    • 7.3.3.2. Key Country Dynamics
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Reimbursement Scenario
    • 7.3.3.5. Competitive Scenario
  • 7.3.4. Spain
    • 7.3.4.1. Spain Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
    • 7.3.4.2. Key Country Dynamics
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Reimbursement Scenario
    • 7.3.4.5. Competitive Scenario
  • 7.3.5. France
    • 7.3.5.1. France Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
    • 7.3.5.2. Key Country Dynamics
    • 7.3.5.3. Regulatory Framework
    • 7.3.5.4. Reimbursement Scenario
    • 7.3.5.5. Competitive Scenario
  • 7.3.6. Italy
    • 7.3.6.1. Italy Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
    • 7.3.6.2. Key Country Dynamics
    • 7.3.6.3. Regulatory Framework
    • 7.3.6.4. Reimbursement Scenario
    • 7.3.6.5. Competitive Scenario
  • 7.3.7. Denmark
    • 7.3.7.1. Denmark Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
    • 7.3.7.2. Key Country Dynamics
    • 7.3.7.3. Regulatory Framework
    • 7.3.7.4. Reimbursement Scenario
    • 7.3.7.5. Competitive Scenario
  • 7.3.8. Sweden
    • 7.3.8.1. Sweden Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
    • 7.3.8.2. Key Country Dynamics
    • 7.3.8.3. Regulatory Framework
    • 7.3.8.4. Reimbursement Scenario
    • 7.3.8.5. Competitive Scenario
  • 7.3.9. Norway
    • 7.3.9.1. Norway Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
    • 7.3.9.2. Key Country Dynamics
    • 7.3.9.3. Regulatory Framework
    • 7.3.9.4. Reimbursement Scenario
    • 7.3.9.5. Competitive Scenario
• 7.4. Asia Pacific
  • 7.4.1. Asia-Pacific Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
  • 7.4.2. Japan
    • 7.4.2.1. Japan Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
    • 7.4.2.2. Key Country Dynamics
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Scenario
    • 7.4.2.5. Competitive Scenario
  • 7.4.3. China
    • 7.4.3.1. China Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
    • 7.4.3.2. Key Country Dynamics
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Scenario
    • 7.4.3.5. Competitive Scenario
  • 7.4.4. India
    • 7.4.4.1. India Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
    • 7.4.4.2. Key Country Dynamics
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Scenario
    • 7.4.4.5. Competitive Scenario
  • 7.4.5. South Korea
    • 7.4.5.1. South Korea Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
    • 7.4.5.2. Key Country Dynamics
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Reimbursement Scenario
    • 7.4.5.5. Competitive Scenario
  • 7.4.6. Thailand
    • 7.4.6.1. Thailand Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
    • 7.4.6.2. Key Country Dynamics
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Reimbursement Scenario
    • 7.4.6.5. Competitive Scenario
  • 7.4.7. Australia
    • 7.4.7.1. Australia Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
    • 7.4.7.2. Key Country Dynamics
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Reimbursement Scenario
    • 7.4.7.5. Competitive Scenario
• 7.5. Latin America
  • 7.5.1. Latin America Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Brazil Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
    • 7.5.2.2. Key Country Dynamics
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Scenario
    • 7.5.2.5. Competitive Scenario
  • 7.5.3. Argentina
    • 7.5.3.1. Argentina Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
    • 7.5.3.2. Key Country Dynamics
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Scenario
    • 7.5.3.5. Competitive Scenario
• 7.6. MEA
  • 7.6.1. MEA Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
  • 7.6.2. South Africa
    • 7.6.2.1. South Africa Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
    • 7.6.2.2. Key Country Dynamics
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Scenario
    • 7.6.2.5. Competitive Scenario
  • 7.6.3. Saudi Arabia
    • 7.6.3.1. Saudi Arabia Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
    • 7.6.3.2. Key Country Dynamics
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Scenario
    • 7.6.3.5. Competitive Scenario
  • 7.6.4. UAE
    • 7.6.4.1. UAE Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
    • 7.6.4.2. Key Country Dynamics
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Scenario
    • 7.6.4.5. Competitive Scenario
  • 7.6.5. Kuwait
    • 7.6.5.1. Kuwait Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
    • 7.6.5.2. Key Country Dynamics
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Scenario
    • 7.6.5.5. Competitive Scenario

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
  • 8.2.1. New Product Launch
  • 8.2.2. Partnerships
  • 8.2.3. Acquisition
  • 8.2.4. Collaboration
  • 8.2.5. Funding
• 8.3. Key Company Market Share Analysis, 2024
• 8.4. Company Heat Map Analysis
• 8.5. Company Profiles
  • 8.5.1. R-Biopharm AG
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. EUROIMMUN Medizinische Labordiagnostika AG (PerkinElmer, Inc.)
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. DASIT Group SPA
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. AESKU.GROUP GmbH
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. bioMerieux
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Danaher
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. AbbVie, Inc
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Thermo Fisher Scientific, Inc
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. Stallergenes Greer
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Minaris Medical America, Inc.
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives
  • 8.5.11. Siemens Healthcare GmbH
    • 8.5.11.1. Overview
    • 8.5.11.2. Financial Performance
    • 8.5.11.3. Product Benchmarking
    • 8.5.11.4. Strategic Initiatives
  • 8.5.12. Omega Diagnostics Group PLC
    • 8.5.12.1. Overview
    • 8.5.12.2. Financial Performance
    • 8.5.12.3. Product Benchmarking
    • 8.5.12.4. Strategic Initiatives
  • 8.5.13. HYCOR Biomedical
    • 8.5.13.1. Overview
    • 8.5.13.2. Financial Performance
    • 8.5.13.3. Product Benchmarking
    • 8.5.13.4. Strategic Initiatives
  • 8.5.14. Lincoln Diagnostics, Inc.
    • 8.5.14.1. Overview
    • 8.5.14.2. Financial Performance
    • 8.5.14.3. Product Benchmarking
    • 8.5.14.4. Strategic Initiatives
  • 8.5.15. Alcon
    • 8.5.15.1. Overview
    • 8.5.15.2. Financial Performance
    • 8.5.15.3. Product Benchmarking
    • 8.5.15.4. Strategic Initiatives
  • 8.5.16. HOB Biotech Group Corp., Ltd.
    • 8.5.16.1. Overview
    • 8.5.16.2. Financial Performance
    • 8.5.16.3. Product Benchmarking
    • 8.5.16.4. Strategic Initiatives
  • 8.5.17. AbbVie Inc.
    • 8.5.17.1. Overview
    • 8.5.17.2. Financial Performance
    • 8.5.17.3. Product Benchmarking
    • 8.5.17.4. Strategic Initiatives
  • 8.5.18. Allergy Therapeutics
    • 8.5.18.1. Overview
    • 8.5.18.2. Financial Performance
    • 8.5.18.3. Product Benchmarking
    • 8.5.18.4. Strategic Initiatives
  • 8.5.19. Sanofi
    • 8.5.19.1. Overview
    • 8.5.19.2. Financial Performance
    • 8.5.19.3. Product Benchmarking
    • 8.5.19.4. Strategic Initiatives
  • 8.5.20. Pfizer Inc.
    • 8.5.20.1. Overview
    • 8.5.20.2. Financial Performance
    • 8.5.20.3. Product Benchmarking
    • 8.5.20.4. Strategic Initiatives
  • 8.5.21. Teva Pharmaceutical Industries Ltd.
    • 8.5.21.1. Overview
    • 8.5.21.2. Financial Performance
    • 8.5.21.3. Product Benchmarking
    • 8.5.21.4. Strategic Initiatives
  • 8.5.22. Sun Pharmaceutical Industries Ltd.
    • 8.5.22.1. Overview
    • 8.5.22.2. Financial Performance
    • 8.5.22.3. Product Benchmarking
    • 8.5.22.4. Strategic Initiatives
  • 8.5.23. GSK plc
    • 8.5.23.1. Overview
    • 8.5.23.2. Financial Performance
    • 8.5.23.3. Product Benchmarking
    • 8.5.23.4. Strategic Initiatives
  • 8.5.24. F. Hoffmann-La Roche Ltd.
    • 8.5.24.1. Overview
    • 8.5.24.2. Financial Performance
    • 8.5.24.3. Product Benchmarking
    • 8.5.24.4. Strategic Initiatives
  • 8.5.25. Merck & Co., Inc.
    • 8.5.25.1. Overview
    • 8.5.25.2. Financial Performance
    • 8.5.25.3. Product Benchmarking
    • 8.5.25.4. Strategic Initiatives
  • 8.5.26. Astellas Pharma Inc.
    • 8.5.26.1. Overview
    • 8.5.26.2. Financial Performance
    • 8.5.26.3. Product Benchmarking
    • 8.5.26.4. Strategic Initiatives